Ken Griffin Pyxis Oncology, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,000 shares of PYXS stock, worth $32,580. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,000
Previous 11,300
20.35%
Holding current value
$32,580
Previous $48,000
39.58%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding PYXS
# of Institutions
86Shares Held
28.5MCall Options Held
134KPut Options Held
5K-
Deep Track Capital, LP Greenwich, CT4.18MShares$15.1 Million0.45% of portfolio
-
Laurion Capital Management LP New York, NY3.86MShares$14 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$10.1 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.56MShares$9.28 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$7.46 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $127M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...